


Pemigatinib

Chemical Properties

CAS No. :	1513857-77-6
Formula:	C ₂₄ H ₂₇ F ₂ N ₅ O ₄
Molecular Weight:	487.5
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Pemigatinib (INCB054828) is an orally active, selective inhibitor of FGFR, with IC ₅₀ values of 0.4 nM for FGFR1, 0.5 nM for FGFR2, 1.2 nM for FGFR3, and 30 nM for FGFR4.
Targets(IC ₅₀)	FGFR
In vitro	In cells expressing FGFR2-CLIP1 fusion are sensitive to Pemigatinib (INCB054828; IC ₅₀ value of 10.16 nM)[3].

Solubility Information

Solubility	DMSO: 26.58 mg/mL (54.52 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 0.1 mg/mL (0.21 mM),Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0513 mL	10.2564 mL	20.5128 mL
5 mM	0.4103 mL	2.0513 mL	4.1026 mL
10 mM	0.2051 mL	1.0256 mL	2.0513 mL
50 mM	0.041 mL	0.2051 mL	0.4103 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. *J Cutan Pathol*. 2018 Oct;45(10):786-790.
- Lidsky M E, Wang Z, Lu M, et al. Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies. *npj Precision Oncology*. 2022, 6(1): 1-17.
- Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. *Pharmacol Res*. 2020 Jan;151:104567.
- Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. *Cold Spring Harb Mol Case Stud*. 2019 Aug 1;5(4).

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481